by Portfolio Grader | March 26, 2014 11:00 am
The grades of seven biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Northwest Biotherapeutics, Inc. (NWBO) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. In Portfolio Grader’s specific subcategories of Earnings Momentum and Sales Growth, NWBO also gets A’s. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
Pharmacyclics, Inc. (PCYC) boosts its rating from a C to a B this week. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of PCYC stock.
This is a strong week for Acorda Therapeutics, Inc. (ACOR). The company’s rating climbs to B from the previous week’s C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock price has risen 6.2% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
This week, Stemline Therapeutics, Inc. (STML) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). For more information, get Portfolio Grader’s complete analysis of STML stock.
This week, Seattle Genetics, Inc. (SGEN) pushes up from a C to a B rating. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
Amgen (AMGN) gets a higher grade this week, advancing from a B last week to an A. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The current dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
BioMarin Pharmaceutical (BMRN) improves from a C to a B rating this week. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of BMRN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2014/03/7-biotechnology-stocks-to-buy-now-nwbo-pcyc-acor-4/
Short URL: http://invstplc.com/1juf0CS
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.